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T oll-like receptors are a family of germline-encoded pattern recognition receptors essential to the detection of microbial components (1) . Known for their role in innate immunity, TLR detect a wide range of pathogen-associated molecular patterns (PAMP). The genes encoding human TLR are dispersed throughout the genome, with the exception of TLR1, TLR6, and TLR10, which lie in a single locus on chromosome 4. TLR2, in combination with TLRs 1, 6, and possibly 10, recognize different PAMP (2) (3) (4) . Pertinent to our current study, the TLR1/2 heterodimer recognizes triacylated lipopeptides isolated from bacterial pathogens or produced synthetically (Pam 3 CSK 4 ). (8) . However, two nonsynonymous coding variants associated with clinical phenotypes rs4833095 (Asn248Ser) and rs5743618 (Ser602Ile) may play a role. In whites, the minor alleles of these coding variants (rs5743618T and rs4833095C) have been associated with increased whole-blood cytokine responses and increased TLR1 surface expression on monocytes due to enhanced trafficking to the cell surface rather than changes in mRNA or total-cell protein levels (9) (10) (11) (12) . The rs5743618 (Ser602Ile) coding variant also was shown to confer increased Pam 3 CSK 4 -induced NF-kB reporter activity in transfected epithelial cell lines that do not express TLR1 (9, 13) . We also identified a single nucleotide polymorphism (SNP) in the TLR1 promoter in high LD with these SNP in which the minor allele rs5743551G is highly associated with death in sepsis (9) . The consequences of these polymorphisms with respect to T cell function have yet to be explored.
Multiple TLR are expressed in T cells and are capable of modulating the function of various T cell subsets. CD4 +
CD25
+ FOXP3 + regulatory T cells (Treg) are pivotal to the suppression of cellular immune responses. Important to these studies, TLR1/2 agonists were shown to impair Treg suppressive capacity in humans (14, 15) . Of interest, this effect was only observed in a subset of subjects, implying interindividual variation (14) . In this study, we tested whether common genetic variation in TLR1 affects TLR1/2 agonistinduced changes in Treg and effector T cell (Teff) function. 
Materials and Methods

Study subjects
We obtained fresh peripheral blood, frozen PBMC, and DNA from healthy volunteers from whom written informed consent was obtained. This work was approved by the Benaroya Research Institute and the University of Washington human subjects committees.
Genotyping
We genotyped DNA for three SNP in TLR1: rs5743618, rs4833095, and rs5743551 by TaqMan PCR-based allelic discrimination. We identified white individuals who carried two copies of the haplotype for the three minor alleles (rs5743618T, rs5743551G, rs4833095C) and age-and gender-matched controls carrying two copies of the haplotype for the three major alleles (rs5743618G, rs5743551A, rs4833095T).
Treg isolation
Natural Treg (nTreg) from freshly isolated PBMC were sorted by flow cytometry for the CD4 + cells expressing the highest 3-5% of CD25 (16) . The mean percentage of FOXP3 + T cells was 90%.
CFSE-based suppression assay
2 Teff were isolated from thawed frozen autologous or heterologous donors' PBMC by negative selection with MicroBeads to CD4 and CD25 (Miltenyi Biotec) and labeled with CFSE (16) . nTreg and Teff were cocultured, at a ratio of 1:2, with anti-CD3/anti-CD28-coated Dynabeads (Invitrogen) at a ratio of 1:10 (beads/Teff) in the presence of media, Pam 3 CSK 4 (1 mg/ml; InvivoGen), 0114:B4 LPS (1 mg/ml; InvivoGen), peptidoglycan (100 ng/ml; Sigma-Fluka), or exogenous IL-6 (50 ng/ml; BD Pharmingen). On day 4, cells were stained for anti-CD4 and anti-CD25 (BioLegend) and analyzed by flow cytometry. Data were excluded from analysis when suppression was ,10% in media-treated cultures. For STAT3 inhibition, CD4 + T cells were incubated with phosphorylation inhibitor of STAT3 (Stattic V; Santa Cruz Biotechnology) at 1200 ng/ml for 1 h, washed, and cultured as above.
We calculated the percentage reduction in suppression in two stages (Supplemental Fig. 1 ). First, the percentage suppression was calculated as [(%Teff alone proliferation 2 %Treg:Teff coculture proliferation)/%Teff alone proliferation] 3 100. We then determined the difference in the percentage suppression between cocultures treated with PAMP or media alone and expressed this as a percentage of media alone: [(% suppression media treated 2 % suppression PAMP treated)/% suppression media treated] 3 100.
TLR1 staining
PBMC were stained with human anti-CD4 (RPA-T4; BioLegend) and anti-TLR1 (GD2.F4; BioLegend), anti-TLR5 (624915; R&D Systems), or isotype control. For a subset, this was followed by intracellular staining using anti-FOXP3 (206D; BioLegend) and a FOXP3 Fix/Perm Buffer Set (BioLegend).
Cytokine measurement
Cell culture supernatants (25 ml) were collected after 48 h of autologous coculture of Treg:Teff or Teff-alone cultures described above. Cytokines were measured by electrochemiluminesence multiplex immunoassay (Meso Scale Discovery, Rockville, MD).
Statistical analysis
We used two-tailed unpaired t tests, two-tailed paired t tests, or a two-tailed nonparametric (Spearman) correlation, as indicated.
Results and Discussion
Minor allele haplotype is associated with enhanced surface expression of TLR1 We (9) and other investigators (10, 11) showed that the minor alleles of nonsynonymous coding polymorphisms in TLR1 (rs5743618T and rs4833095C) are associated with altered cell surface expression of TLR1 on monocytes. We used flow cytometry to determine whether these TLR1 alleles also alter cell surface expression of TLR1 on T lymphocytes. We obtained PBMCs from white subjects carrying two copies of the TLR1 "minor" allele haplotype (rs5743618T, rs5743551G, rs4833095C) and control subjects carrying two copies of the "major" allele haplotype (rs5743618G, rs5743551A, rs4833095T). The study subjects were predominantly male (63%) and had a mean age of 36 6 14 y. PBMC were stained for surface expression of CD4 and TLR1. Subjects homozygous for the TLR1 minor allele haplotype had a significantly higher TLR1 median fluorescence intensity (MFI) on CD4 + T cells (Fig. 1A) than did those homozygous for the TLR1 major allele haplotype (p = 0.004). Cell surface expression of TLR5 did not differ by TLR1 haplotype (Fig. 1B) . When we further differentiated T cells by FOXP3 staining, we found that both CD4 + FOXP3 + and CD4 + FOXP3 2 T cells from subjects homozygous for the TLR1 minor allele haplotype had a significantly higher percentage of cells expressing TLR1 relative to the major allele haplotype (Supplemental Fig. 2A, 2B) . Thus, TLR1 variants associated with increased expression of TLR1 on peripheral blood monocytes are also associated with enhanced TLR1 surface expression on both Treg and Teff. (14, 15) . We then compared the magnitude of this Pam 3 CSK 4 -induced effect in cultures of cells from subjects with either the minor or major allele TLR1 haplotypes. We found that, in the presence of Pam 3 CSK 4 , Treg suppression of Teff was impaired to a greater degree in cells from subjects harboring the TLR1 minor allele haplotype compared with those with the major allele haplotype (Fig. 2A, p = 0.02) . Evidence that the effect of the TLR1 haplotypes is specific to TLR1/2-mediated responses was provided by the finding that there were no haplotype-specific effects observed when cocultures were treated with LPS (p = 0.48), a TLR4 agonist, or peptidoglycan, a TLR2 agonist that does not require TLR1 (p = 0.51) (2) . Our data show that Pam 3 CSK 4 impairs Treg suppression of Teff proliferation to a greater extent in subjects who harbor the TLR1 minor allele haplotype that confers higher TLR1 surface expression.
Absence of Pam 3 CSK 4 -induced effect on Teff suppression in absence of Treg
The proliferation or activation state of Teff can change their sensitivity to Treg-mediated suppression. To assess whether Pam 3 CSK 4 altered the proliferation of Teff in the absence of Treg, we measured the proliferation of Teff with anti-CD3/ anti-CD28-coated beads in the presence of TLR agonists or media alone. There was no significant difference in proliferation of Teff between TLR1 haplotypes for media-treated or any of the TLR-treated cultures (Fig. 2B) (Fig. 2C ). This suggests that increased TLR1 surface expression on Treg is not sufficient to observe the effect of TLR1 variants on Pam 3 CSK 4 -induced alteration of Treg suppression. In contrast, when we incubated Treg isolated from a subject carrying the major haplotype with Teff from subjects carrying either the minor or major allele TLR1 haplotype, the haplotype-dependent Pam 3 CSK 4 -induced reduction in Treg suppression was observed (p = 0.04, Fig. 2D ). These data suggest that increased stimulation of Teff conferred by the minor allele haplotype of TLR1 causes Teff resistance to Treg suppression.
Impaired Treg suppression correlates with higher IL-6 production and is reversed by STAT3 inhibition
Proinflammatory cytokine production, particularly IL-6, is associated with impaired Treg suppression (18) . Teff resistance to Treg suppression has been implicated in the pathogenesis of several disease states, including psoriasis, diabetes, and relapsing remitting multiple sclerosis, and the IL-6 pathway was shown to mediate this resistance (17, 19, 20) . We reasoned that enhanced cell surface expression of TLR1 on T cells from subjects carrying the minor allele haplotype would result in increased Pam 3 CSK 4 -induced cytokine levels in the T cell cocultures. We measured cytokine levels in supernatants collected after 48 h of incubation from cocultures of autologous Treg and Teff and the cultures of Teff alone stimulated with TLR agonists in the presence of anti-CD3/anti-CD28-coated beads. In supernatants from cocultures of Teff with Treg, there was a trend toward increased IL-6 production in subjects with the minor allele haplotype; however, this difference did not achieve statistical significance (Fig. 3A) . We found that Pam 3 CSK 4 -induced IL-6 levels were significantly higher in Pam 3 CSK 4 -treated Teff isolated from subjects carrying the minor allele haplotype (p = 0.03, Fig. 3B ). IL-2 and TNF-a levels did not differ by TLR1 genotype for either cultures of Teff alone or cocultures of Treg with Teff ( Supplemental Fig.  2C, 2D) . These data support a model whereby Teff-driven differences in Pam 3 CSK 4 -induced IL-6 production participate in Teff resistance to Treg suppression. Further support for this model was demonstrated through the observed relationship between IL-6 production and the impairment in autologous Treg suppression of Teff. Although IL-6 levels were not significantly different by genotype from the coculture assays, we observed that IL-6 levels in Teff:Treg cocultures had a strong positive correlation with inhibition of Treg suppression (Spearman's r = +0.85, p = 0.002, Fig. 4A ).
To determine whether IL-6 is directly involved in the impairment of Treg suppression in our system, we tested whether inhibition of STAT3 phosphorylation, a key event in IL-6 intracellular signaling, abrogated Teff resistance. We found that STAT3 inhibition decreased the average Pam 3 CSK 4 -mediated impairment of Treg suppression (Fig. 4B) in cocultures with Teff for subjects of both TLR1 haplotypes (p = 0.005). Addition of exogenous IL-6 to cocultures increased major allele Teff resistance, partially abrogating the difference between genotypes (Supplemental Fig. 2E ). In another published study, blockade of IL-6 independently reversed the effects of TLR1/2-mediated impaired Treg suppression (15) . Although other proinflammatory cytokines may be involved in modulating Teff resistance in this system, these data demonstrate that IL-6 signaling participates in the induction of Teff resistance to Treg suppression in response to TLR1/2 stimulation.
Work from our laboratory and others highlighted a potential role for genetic variation in TLR1 in various immunemediated and inflammatory diseases. In this study, we showed that a haplotype in TLR1 composed of the minor alleles identified in these clinical-association studies is associated with increased Teff resistance to Treg suppression after stimulation with a TLR1/2 agonist. These findings provide a novel potential mechanism through which these TLR1 variants might affect clinical outcomes. For example, Mayerle et al. (5) detected a strong association between the TLR10/1/6 genetic locus and seroprevalence for H. pylori. The most highly associated TLR1 SNP in this study, rs10004195, is in high LD with the two nonsynonymous coding SNPs included in the haplotype in our study (rs4833095 r 2 = +1; rs5743618 r 2 = +0.95). Our data suggest that Teff from subjects bearing the minor alleles at these loci could be resistant to Treg suppression after chronic exposure to TLR1/2 ligands, which are abundant at these mucosal sites. Similar mechanisms could be responsible for associations with asthma through altered immune responses in the respiratory mucosa.
In summary, we showed that white subjects harboring the minor allele TLR1 haplotype rs5743618T, rs5743551G, rs4833095C have greater cell surface expression of TLR1 on both CD4
+ FOXP3 + and CD4 + FOXP3 2 T cells and greater impairment of Treg-mediated suppression of Teff proliferation after treatment with the TLR1/2 agonist Pam 3 CSK 4. This effect is due to Teff resistance and is largely mediated by IL-6 signaling, although other factors may also play a role. These studies highlight the potential importance of common genetic variation in TLR1 in mediating interindividual differences in Treg effects on Teff and provide a new mechanism through which SNP in TLR1 might alter susceptibility to disease states in which Treg:Teff interactions play a key role. 
